Remix Therapeutics Appoints Matthew R. Patterson as Executive Chairman of its Board of Directors

Share this article
Share this article
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the appointment of Matthew R. Patterson as Executive Chairman of the company's Board of Directors. Mr. Patterson is the co-founder and former chairman and CEO of Audentes Therapeutics, a gene therapy company acquired by Astellas Pharma in 2020.
"Matt has had an impressive 30-year career in research, drug development, and the commercialization of innovative therapeutics for both private and publicly held biotechnology companies," said Kevin Bitterman, PhD, Founding Chairman of the Board of Remix Therapeutics and Partner at Atlas Venture. "His knowledge of the industry and experience building and advancing early-stage companies will be invaluable as we shape the path forward for Remix."

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Kevin Bitterman ,Astellas Pharma ,Pete Smith ,Matthewr Patterson ,Amicus Therapeutics ,Vor Biopharma Inc ,Atlas Venture ,Acquisition Corporation ,Homology Medicines Inc ,Alliance For Regenerative Medicine ,Genzyme Corporation ,Remix Therapeutics ,Executive Chairman ,Audentes Therapeutics ,Founding Chairman ,Atlas Venture Entrepreneur ,Strategic Advisor ,Homology Medicines ,Vor Biopharma ,Regenerative Medicine ,கேம்பிரிட்ஜ் ,கேம்பிரிட்ஜ்ஷைர் ,ஒன்றுபட்டது கிஂக்டம் ,கெவின் கசப்பு ,பீட் ஸ்மித் ,அமிகஸ் சிகிச்சை ,அட்லஸ் துணிகர ,கையகப்படுத்தல் நிறுவனம் ,கூட்டணி க்கு மீளுருவாக்கம் மருந்து ,ரீமிக்ஸ் சிகிச்சை ,நிர்வாகி தலைவர் ,ஸ்தாபகம் தலைவர் ,அட்லஸ் துணிகர தொழில்முனைவோர் ,மீளுருவாக்கம் மருந்து ,